Loading presentation...

Present Remotely

Send the link below via email or IM

Copy

Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.

DeleteCancel

JUNE

No description

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of JUNE

NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
JUNE
Clinical
Business
3 Clinical Data Announcements

3 INDs/Trial Initiations

1 Enrollment Completions

1 BLAs/Market Approvals

3 Special Designations
3 IPOs, Follow Ons and Venture Financing

5 Deals and
Collaborations

3 Acquisitions
Clinical Data Announcements

• Bluebird bio reports Beta-thalassemia major and severe sickle cell disease data from HGB-205 Study EHA
• Mesoblast reports positive trial results for the Phase II MPC trial (MPC-300-IV for patients with diabetic nephropathy
• Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

INDs/Trial Initiations
• FDA Cleared Q-Therapeutics IND for the initiation of Phase I/II study for ALS
• Capricor receives FDA Clearance for Phase I/II Study of CAP-1002 for Treatment of Duchenne Muscular Dystrophy
• FDA accepted TxCell’s IND application for the company’s lead product, Ovasave®, currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease

Enrollment Completions
• Cytori Completes Enrollment in US Phase IIb Osteoarthritis Trial

BLAs/Market Approvals
• Vericel Announces Plan to Submit a BLA to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee

Special Designations

• Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma
• Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
• AveXis Gains Orphan Drug Designation from the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy

Clinical
NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
JUNE
NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
JUNE
Business
IPOs, Follow Ons and Venture Financings
1. Celyad raises $100.1 million gross proceeds with NASDAQ IPO
2. Unum Therapeutics Announces $65M Series B Round
3. CytomX Raises 70M in Series D Financing

Deals and Collaborations
4. Bluebird regains rights to CAR-T outside BCMA (B-cell maturation antigen)
5. Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat
HPV-Associated Cancers
6. Seattle Genetics and Unum Therapeutics Enter Into Cancer Immunotherapy Collaboration
7. Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization
of immunotherapies
8. 150M upfront + 850M in common stock

Acquisitions
9. Juno acquires X-Body 21M cash + 23M+ in stock (antibody selection technology – highly stable and functional binding molecules)
10. Integra LifeSciences to Acquire TEI Biosciences and TEI Medical – $312M Cash
11. AMAG Pharmaceuticals to Acquire Cord Blood Registry - $700M

Clinical Data Announcements


• Bluebird bio reports Beta-thalassemia major and severe sickle cell disease data from HGB-205 Study EHA
• Mesoblast reports positive trial results for the Phase II MPC trial (MPC-300-IV for patients with diabetic nephropathy
• Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

INDs/Trial Initiations

• FDA Cleared Q-Therapeutics IND for the initiation of Phase I/II study for ALS
• Capricor receives FDA Clearance for Phase I/II Study of CAP-1002 for Treatment of Duchenne Muscular Dystrophy
• FDA accepted TxCell’s IND application for the company’s lead product, Ovasave®, currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease

Enrollment Completions

• Cytori Completes Enrollment in US Phase IIb Osteoarthritis Trial

BLAs/Market Approvals
• Vericel Announces Plan to Submit a BLA to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee

Special Designations

• Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma
• Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
• AveXis Gains Orphan Drug Designation from the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy

IPOs, Follow Ons and Venture Financings
1. Celyad raises $100.1 million gross proceeds with NASDAQ IPO
2. Unum Therapeutics Announces $65M Series B Round
3. CytomX Raises 70M in Series D Financing

Deals and Collaborations
4. Bluebird regains rights to CAR-T outside BCMA (B-cell maturation antigen)
5. Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers
6. Seattle Genetics and Unum Therapeutics Enter Into Cancer Immunotherapy Collaboration
7. Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization
of immunotherapies
8. 150M upfront + 850M in common stock

Acquisitions
9. Juno acquires X-Body 21M cash + 23M+ in stock (antibody selection technology – highly stable and functional binding molecules)
10. Integra LifeSciences to Acquire TEI Biosciences and TEI Medical – $312M Cash
11. AMAG Pharmaceuticals to Acquire Cord Blood Registry - $700M

Clinical (11)
Business (11)
11
11
Business
Clinical
Clinical Data Announcements


• Bluebird bio reports Beta-thalassemia major and severe sickle cell disease data from HGB-205 Study EHA
• Mesoblast reports positive trial results for the Phase II MPC trial (MPC-300-IV for patients with diabetic nephropathy
• Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

INDs/Trial Initiations
• FDA Cleared Q-Therapeutics IND for the initiation of Phase I/II study for ALS
• Capricor receives FDA Clearance for Phase I/II Study of CAP-1002 for Treatment of Duchenne Muscular Dystrophy
• FDA accepted TxCell’s IND application for the company’s lead product, Ovasave®, currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease

Enrollment Completions

• Cytori Completes Enrollment in US Phase IIb Osteoarthritis Trial

BLAs/Market Approvals
• Vericel Announces Plan to Submit a BLA to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee

Special Designations

• Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma
• Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
• AveXis Gains Orphan Drug Designation from the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy

IPOs, Follow Ons and Venture Financings
1. Celyad raises $100.1 million gross proceeds with NASDAQ IPO
2. Unum Therapeutics Announces $65M Series B Round
3. CytomX Raises 70M in Series D Financing

Deals and Collaborations
4. Bluebird regains rights to CAR-T outside BCMA (B-cell maturation antigen)
5. Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers
6. Seattle Genetics and Unum Therapeutics Enter Into Cancer Immunotherapy Collaboration
7. Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization
of immunotherapies
8. 150M upfront + 850M in common stock

Acquisitions
9. Juno acquires X-Body 21M cash + 23M+ in stock (antibody selection technology – highly stable and functional binding molecules)
10. Integra LifeSciences to Acquire TEI Biosciences and TEI Medical – $312M Cash
11. AMAG Pharmaceuticals to Acquire Cord Blood Registry - $700M

NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
JUNE
Clinical (11)
Business (11)
Business
Clinical
Business (11)
Clinical (11)
Clinical Data Announcements

Bluebird bio reports Beta-thalassemia major and severe sickle cell disease data from HGB-205 Study EHA
Mesoblast reports positive trial results for the Phase II MPC trial (MPC-300-IV for patients with diabetic nephropathy
Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

INDs/Trial Initiations
FDA Cleared Q-Therapeutics IND for the initiation of Phase I/II study for ALS
Capricor receives FDA Clearance for Phase I/II Study of CAP-1002 for Treatment of Duchenne Muscular Dystrophy
FDA accepted TxCell’s IND application for the company’s lead product, Ovasave®, currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease

Enrollment Completions
Cytori Completes Enrollment in US Phase IIb Osteoarthritis Trial

BLAs/Market Approvals
Vericel Announces Plan to Submit a BLA to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee

Special Designations
Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma
Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
AveXis Gains Orphan Drug Designation from the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy

IPOs, Follow Ons and Venture Financings
Celyad raises $100.1 million gross proceeds with NASDAQ IPO
Unum Therapeutics Announces $65M Series B Round
CytomX Raises 70M in Series D Financing

Deals and Collaborations
Bluebird regains rights to CAR-T outside BCMA (B-cell maturation antigen)
Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat
HPV-Associated Cancers
Seattle Genetics and Unum Therapeutics Enter Into Cancer Immunotherapy Collaboration
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization
of immunotherapies
150M upfront + 850M in common stock

Acquisitions
Juno acquires X-Body 21M cash + 23M+ in stock (antibody selection technology – highly stable and functional binding molecules)
Integra LifeSciences to Acquire TEI Biosciences and TEI Medical – $312M Cash
AMAG Pharmaceuticals to Acquire Cord Blood Registry - $700M
Clinical
3
Clinical Data Announcements

2
INDs/Trial Initiations

1
Enrollment Completions

1
BLAs/Market Approvals

3
Special Designations
Business
3
IPOs, Follow Ons and Venture Financing

5
Deals and
Collaborations

3
Acquisitions
NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
JUNE
Clinical Data Announcements


• Bluebird bio reports Beta-thalassemia major and severe sickle cell disease data from HGB-205 Study EHA
• Mesoblast reports positive trial results for the Phase II MPC trial (MPC-300-IV for patients with diabetic nephropathy
• Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

INDs/Trial Initiations

• FDA Cleared Q-Therapeutics IND for the initiation of Phase I/II study for ALS
• Capricor receives FDA Clearance for Phase I/II Study of CAP-1002 for Treatment of Duchenne Muscular Dystrophy
• FDA accepted TxCell’s IND application for the company’s lead product, Ovasave®, currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease

Enrollment Completions

• Cytori Completes Enrollment in US Phase IIb Osteoarthritis Trial

BLAs/Market Approvals
• Vericel Announces Plan to Submit a BLA to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee

Special Designations

• Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma
• Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
• AveXis Gains Orphan Drug Designation from the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy

IPOs, Follow Ons and Venture Financings
1. Celyad raises $100.1 million gross proceeds with NASDAQ IPO
2. Unum Therapeutics Announces $65M Series B Round
3. CytomX Raises 70M in Series D Financing

Deals and Collaborations
4. Bluebird regains rights to CAR-T outside BCMA (B-cell maturation antigen)
5. Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers
6. Seattle Genetics and Unum Therapeutics Enter Into Cancer Immunotherapy Collaboration
7. Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization
of immunotherapies
8. 150M upfront + 850M in common stock

Acquisitions
9. Juno acquires X-Body 21M cash + 23M+ in stock (antibody selection technology – highly stable and functional binding molecules)
10. Integra LifeSciences to Acquire TEI Biosciences and TEI Medical – $312M Cash
11. AMAG Pharmaceuticals to Acquire Cord Blood Registry - $700M

Clinical (11)
Business (11)
IPOs, Follow Ons and Venture Financings
1. Celyad raises $100.1 million gross proceeds with NASDAQ IPO
2. Unum Therapeutics Announces $65M Series B Round
3. CytomX Raises 70M in Series D Financing

Deals and Collaborations
4. Bluebird regains rights to CAR-T outside BCMA (B-cell maturation antigen)
5. Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat
HPV-Associated Cancers
6. Seattle Genetics and Unum Therapeutics Enter Into Cancer Immunotherapy Collaboration
7. Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization
of immunotherapies
8. 150M upfront + 850M in common stock

Acquisitions
9. Juno acquires X-Body 21M cash + 23M+ in stock (antibody selection technology – highly stable and functional binding molecules)
10. Integra LifeSciences to Acquire TEI Biosciences and TEI Medical – $312M Cash
11. AMAG Pharmaceuticals to Acquire Cord Blood Registry - $700M

Business
3 IPOs, Follow Ons and Venture Financing

5 Deals and
Collaborations

3 Acquisitions
Clinical
3 Clinical Data Announcements

2 INDs/Trial Initiations

1 Enrollment Completions

1 BLAs/Market Approvals

3 Special Designations
Clinical Data Announcements

• Bluebird bio reports Beta-thalassemia major and severe sickle cell disease data from HGB-205 Study EHA
• Mesoblast reports positive trial results for the Phase II MPC trial (MPC-300-IV for patients with diabetic nephropathy
• Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

INDs/Trial Initiations
• FDA Cleared Q-Therapeutics IND for the initiation of Phase I/II study for ALS
• Capricor receives FDA Clearance for Phase I/II Study of CAP-1002 for Treatment of Duchenne Muscular Dystrophy
• FDA accepted TxCell’s IND application for the company’s lead product, Ovasave®, currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease

Enrollment Completions
• Cytori Completes Enrollment in US Phase IIb Osteoarthritis Trial

BLAs/Market Approvals
• Vericel Announces Plan to Submit a BLA to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee

Special Designations

• Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma
• Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
• AveXis Gains Orphan Drug Designation from the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy

NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
JUNE
NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
JUNE
Business (11)
Clinical (11)
Clinical Data Announcements


• Bluebird bio reports Beta-thalassemia major and severe sickle cell disease data from HGB-205 Study EHA
• Mesoblast reports positive trial results for the Phase II MPC trial (MPC-300-IV for patients with diabetic nephropathy
• Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

INDs/Trial Initiations
• FDA Cleared Q-Therapeutics IND for the initiation of Phase I/II study for ALS
• Capricor receives FDA Clearance for Phase I/II Study of CAP-1002 for Treatment of Duchenne Muscular Dystrophy
• FDA accepted TxCell’s IND application for the company’s lead product, Ovasave®, currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease

Enrollment Completions

• Cytori Completes Enrollment in US Phase IIb Osteoarthritis Trial

BLAs/Market Approvals
• Vericel Announces Plan to Submit a BLA to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee

Special Designations

• Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma
• Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
• AveXis Gains Orphan Drug Designation from the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy

IPOs, Follow Ons and Venture Financings
1. Celyad raises $100.1 million gross proceeds with NASDAQ IPO
2. Unum Therapeutics Announces $65M Series B Round
3. CytomX Raises 70M in Series D Financing

Deals and Collaborations
4. Bluebird regains rights to CAR-T outside BCMA (B-cell maturation antigen)
5. Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers
6. Seattle Genetics and Unum Therapeutics Enter Into Cancer Immunotherapy Collaboration
7. Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization
of immunotherapies
8. 150M upfront + 850M in common stock

Acquisitions
9. Juno acquires X-Body 21M cash + 23M+ in stock (antibody selection technology – highly stable and functional binding molecules)
10. Integra LifeSciences to Acquire TEI Biosciences and TEI Medical – $312M Cash
11. AMAG Pharmaceuticals to Acquire Cord Blood Registry - $700M

NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
JUNE
3
IPOs, Follow Ons and Venture Financing



5
Deals and Collaborations



3
Acquisitions
3
Clinical Data Announcements



3
INDs/Trial Initiations



1
Enrollment
Completions


1
BLAs/
Market
Approvals


3
Special Designations
Clinical Data Announcements

Bluebird bio reports Beta-thalassemia major and severe sickle cell disease data from HGB-205 Study EHA
Mesoblast reports positive trial results for the Phase II MPC trial (MPC-300-IV for patients with diabetic nephropathy
Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

INDs/Trial Initiations
FDA Cleared Q-Therapeutics IND for the initiation of Phase I/II study for ALS
Capricor receives FDA Clearance for Phase I/II Study of CAP-1002 for Treatment of Duchenne Muscular Dystrophy
FDA accepted TxCell’s IND application for the company’s lead product, Ovasave®, currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease

Enrollment Completions
Cytori Completes Enrollment in US Phase IIb Osteoarthritis Trial

BLAs/Market Approvals
Vericel Announces Plan to Submit a BLA to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee

Special Designations
Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma
Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
AveXis Gains Orphan Drug Designation from the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy

IPOs, Follow Ons and Venture Financings
Celyad raises $100.1 million gross proceeds with NASDAQ IPO
Unum Therapeutics Announces $65M Series B Round
CytomX Raises 70M in Series D Financing

Deals and Collaborations
Bluebird regains rights to CAR-T outside BCMA (B-cell maturation antigen)
Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat
HPV-Associated Cancers
Seattle Genetics and Unum Therapeutics Enter Into Cancer Immunotherapy Collaboration
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization
of immunotherapies
150M upfront + 850M in common stock

Acquisitions
Juno acquires X-Body 21M cash + 23M+ in stock (antibody selection technology – highly stable and functional binding molecules)
Integra LifeSciences to Acquire TEI Biosciences and TEI Medical – $312M Cash
AMAG Pharmaceuticals to Acquire Cord Blood Registry - $700M
Clinical Data Announcements

Bluebird bio reports Beta-thalassemia major and severe sickle cell disease data from HGB-205 Study EHA
Mesoblast reports positive trial results for the Phase II MPC trial (MPC-300-IV for patients with diabetic nephropathy
Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

INDs/Trial Initiations
FDA Cleared Q-Therapeutics IND for the initiation of Phase I/II study for ALS
Capricor receives FDA Clearance for Phase I/II Study of CAP-1002 for Treatment of Duchenne Muscular Dystrophy
FDA accepted TxCell’s IND application for the company’s lead product, Ovasave®, currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease

Enrollment Completions
Cytori Completes Enrollment in US Phase IIb Osteoarthritis Trial

BLAs/Market Approvals
Vericel Announces Plan to Submit a BLA to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee

Special Designations
Lion Biotechnologies Receives Orphan Drug Designation for LN-144 for the Treatment of Malignant Melanoma
Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
AveXis Gains Orphan Drug Designation from the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy

IPOs, Follow Ons and Venture Financings
Celyad raises $100.1 million gross proceeds with NASDAQ IPO
Unum Therapeutics Announces $65M Series B Round
CytomX Raises 70M in Series D Financing

Deals and Collaborations
Bluebird regains rights to CAR-T outside BCMA (B-cell maturation antigen)
Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat
HPV-Associated Cancers
Seattle Genetics and Unum Therapeutics Enter Into Cancer Immunotherapy Collaboration
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization
of immunotherapies
150M upfront + 850M in common stock

Acquisitions
Juno acquires X-Body 21M cash + 23M+ in stock (antibody selection technology – highly stable and functional binding molecules)
Integra LifeSciences to Acquire TEI Biosciences and TEI Medical – $312M Cash
AMAG Pharmaceuticals to Acquire Cord Blood Registry - $700M
NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
JUNE
NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
SEPTEMBER
NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
SEPTEMBER
NEWS OF THE MONTH:
Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies
• 150M upfront + 850M in common stock
SEPT.
Full transcript